Bailard Inc. Has $13.90 Million Stock Position in Danaher Corporation $DHR

Bailard Inc. cut its stake in shares of Danaher Corporation (NYSE:DHR) by 7.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 70,097 shares of the conglomerate’s stock after selling 5,900 shares during the period. Bailard Inc.’s holdings in Danaher were worth $13,897,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in DHR. White Pine Capital LLC boosted its holdings in shares of Danaher by 1.4% in the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after buying an additional 49 shares during the last quarter. SOL Capital Management CO raised its position in Danaher by 2.8% during the third quarter. SOL Capital Management CO now owns 1,829 shares of the conglomerate’s stock worth $363,000 after acquiring an additional 50 shares in the last quarter. Boyd Watterson Asset Management LLC OH lifted its stake in Danaher by 2.1% in the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after acquiring an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its position in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares during the period. Finally, Howard Capital Management Group LLC increased its stake in shares of Danaher by 4.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock worth $230,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $234.11 on Wednesday. The company has a market cap of $165.36 billion, a price-to-earnings ratio of 48.27, a PEG ratio of 4.20 and a beta of 0.89. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a fifty day moving average price of $229.17 and a 200-day moving average price of $212.44.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the firm earned $1.71 earnings per share. Danaher’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.5%. Danaher’s payout ratio is presently 26.39%.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 30,248 shares of company stock worth $6,609,663. 11.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. KeyCorp reiterated an “overweight” rating on shares of Danaher in a research note on Thursday, December 18th. The Goldman Sachs Group began coverage on Danaher in a research report on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price objective for the company. Wells Fargo & Company lifted their target price on Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Deutsche Bank Aktiengesellschaft increased their price target on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Finally, Robert W. Baird set a $247.00 price objective on shares of Danaher in a research report on Wednesday, October 22nd. Twenty-one investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.87.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.